| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Urolithins are gut microbiota–derived dibenzopyran-6-one metabolites formed from ellagitannins → ellagic acid. They are the bioactive, systemically relevant forms responsible for most of the anticancer, mitochondrial, and signaling effects attributed to pomegranate and berry consumption. Ellagic acid itself is largely confined to the gut lumen; urolithins are what reach circulation and tissues. Urolithin A (UA), Most studied; mitophagy, anticancer, anti-inflammatory Humans fall into urolithin metabotypes: Metabotype Description Approx. Population A Produces UA (best profile) ~40% B Produces UB ± UA ~25–30% 0 Non-producer ~30% ROS Modulation (Context-Dependent) Cancer cells: -Mild ROS ↑ or redox stress → apoptosis, growth arrest Normal cells: -ROS ↓, improved mitochondrial efficiency This duality is why urolithins are less chemo-antagonistic than classic antioxidants. Anticancer Signaling ↓ PI3K/AKT/mTOR ↓ Wnt/β-catenin ↓ NF-κB, STAT3 Cell-cycle arrest (G1/S) Unlike sulforaphane or NAC, urolithins: -Do not strongly upregulate NRF2 in cancer cells -May normalize NRF2 signaling in normal cellsDirect Urolithin A Supplements: Bypass microbiome dependency Urolithin A–type activity — Cancer vs Normal Cell Effects
|
| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| 4857- | Uro, | Evaluation and comparison of the anti-proliferative and anti-metastatic effects of urolithin A and urolithin B against esophageal cancer cells: an in vitro and in silico study |
| - | in-vitro, | ESCC, | KYSE-30 |
| 4838- | Uro, | The Therapeutic Potential of Urolithin A for Cancer Treatment and Prevention |
| - | Review, | Var, | NA |
| 4854- | Uro, | Urolithins: Emerging natural compound targeting castration-resistant prostate cancer (CRPC) |
| - | Review, | Pca, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:383 Target#:1110 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid